These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16850121)

  • 1. Current topics and the clinical effects of target-based antineoplastic agents.
    Maehara Y; Egashira A; Kakeji Y
    Int J Clin Oncol; 2006 Jun; 11(3):164-6. PubMed ID: 16850121
    [No Abstract]   [Full Text] [Related]  

  • 2. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 3. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
    Carmi C; Mor M; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2012 Dec; 84(11):1388-99. PubMed ID: 22885287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Toxic Effects of Targeted Cancer Therapies.
    Moslehi JJ
    N Engl J Med; 2016 Oct; 375(15):1457-1467. PubMed ID: 27732808
    [No Abstract]   [Full Text] [Related]  

  • 6. [Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
    Grimm CF; Blum HE; Geissler M
    Dtsch Med Wochenschr; 2005 May; 130(21):1318-22. PubMed ID: 15902620
    [No Abstract]   [Full Text] [Related]  

  • 7. Multitarget tyrosine kinase inhibition: [and the winner is...].
    Verweij J; de Jonge M
    J Clin Oncol; 2007 Jun; 25(17):2340-2. PubMed ID: 17557945
    [No Abstract]   [Full Text] [Related]  

  • 8. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.
    Zámečníkova A
    Expert Opin Drug Discov; 2014 Jan; 9(1):77-92. PubMed ID: 24294890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heritable resistance to tyrosine kinase inhibitors.
    Ong ST
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):454-7. PubMed ID: 25322326
    [No Abstract]   [Full Text] [Related]  

  • 11. Bad patients meet good drugs.
    Lacal JC
    Clin Transl Oncol; 2006 Apr; 8(4):225-7. PubMed ID: 16648096
    [No Abstract]   [Full Text] [Related]  

  • 12. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
    Engelman JA; Settleman J
    Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].
    Joensuu H
    Duodecim; 2012; 128(21):2261-8. PubMed ID: 23210289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase inhibitors: novel tools in cancer therapy.
    Marmé D
    Urologe A; 2004 Sep; 43 Suppl 3():S148. PubMed ID: 15148578
    [No Abstract]   [Full Text] [Related]  

  • 15. Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
    Howard SA; Rosenthal MH; Jagannathan JP; Krajewski KM; Shinagare AB; Ramaiya NH; Tirumani SH
    AJR Am J Roentgenol; 2015 May; 204(5):919-32. PubMed ID: 25905926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mini-review: bmx kinase inhibitors for cancer therapy.
    Jarboe JS; Dutta S; Velu SE; Willey CD
    Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):228-38. PubMed ID: 23198769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations.
    Thirumal Raj A; Patil S; Ranadheer R; Chandini R
    Oral Oncol; 2017 Oct; 73():172. PubMed ID: 28923250
    [No Abstract]   [Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.
    Tibes R; Trent J; Kurzrock R
    Annu Rev Pharmacol Toxicol; 2005; 45():357-84. PubMed ID: 15822181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular side effects of small molecule therapies for cancer.
    Pun SC; Neilan TG
    Eur Heart J; 2016 Sep; 37(36):2742-2745. PubMed ID: 27694541
    [No Abstract]   [Full Text] [Related]  

  • 20. Tyrosine kinase inhibitors in cancer therapeutics: great expectations from small molecules.
    Ansar ZA; Moatter T
    J Coll Physicians Surg Pak; 2014 Jul; 24(7):453-4. PubMed ID: 25052963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.